Hematology and interne medicine department, Ambroise Paré hospital - APHP
Boulogne-Billancourt, 92100, France
Location status: Recruiting
NCT Number: NCT06458504
We propose to demonstrate that HIV-1 and SARS-CoV-2 are capable of targeting long-lived HSPC with self-renewal capacities. These progenitors, thus transformed into host cells, can give rise to a durable source of infected cells with an impact on hematopoiesis.
Interested in participating?
Request Info18 year and older
All sexes
Observational
Boulogne-Billancourt, 92100, France
Location status: Recruiting
Virus-induced immunosuppression is the transient or persistent decline of immune cell counts and/or function caused by a virus, favouring its persistence in the host organisms. When sustained, triggered by acute viral replication or maintained by chronic viral infections, virus-induced immunosuppression is a life-threatening condition. It is notoriously observed in chronic HIV-1 infection and even in a considerable fraction of antiretroviral-treated HIV-infected individuals. It is also observed in some individuals recovering from severe and mild-to-moderate COVID-19. Its mechanisms are elusive and efficient therapeutic options are not available. Virus-induced immunosuppression may occur in the periphery (affecting circulating immune cells) or in the bone marrow, affecting hematopoietic stem and progenitor cells (HSPC) and hematopoiesis. Several viruses can infect HSPCs. HIV-1 can directly infect HSC, negatively impacting HSC function and the whole stem cell environment of the bone marrow. Whether HSC can be productively infected by SARS-CoV-2 or just targeted and modulated by it remains uncertain and further studies are required to determine HSPC susceptibility or viral sensing for SARS-CoV-2. Therefore, we will i) Evaluate which hematopoietic stem and progenitor cells (HSPC) are targeted by HIV-1 (in vivo and ex vivo) and SARS-CoV-2 (ex vivo); ii) Evaluate whether these infected HSPC would modulate the bone marrow environment by upregulating inflammatory cytokines detrimental to lymphopoiesis.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
HIV patients :
Healthy subjects without HIV - patients with a BM biopsy or myelogram performed as part of their care for a suspected hematological pathology.
Management at Ambroise Paré Hospital.
Exclusion criteria
-
Time frame: at 1 year
Evaluate whether these infected HSPC would modulate the bone marrow environment by upregulating inflammatory cytokines detrimental to lymphopoiesis.
Contact information is provided by the study sponsor or research team.
Claude CAPRON, MD, PhD
CONTACT
Fernando REAL, PhD
CONTACT
Assistance Publique - Hôpitaux de Paris
Other
Virus-induced Immunosuppression Via Infection of Hematopoietic Progenitors
Acronym: MEGAHOST
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06517693
HIV-1
Los Angeles, California, United States
View Trial DetailsNCT07481175
HIV-1
Aarhus, Denmark
View Trial DetailsNCT06252402
HIV-1
Duarte, California, United States
View Trial DetailsNCT06967753
HIV, HIV-1
Buenos Aires, Buenos Aires F.D., Argentina
View Trial Details